311PEarly results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC). (23rd October 2018) - Shum, M; Assikis, V J; Savulsky, C; Zhu, W; Iyer, P; Xing, D; Berman, C; Lokker, N A; Alvarez, R H